Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Zimmer Biomet Holdings (ZBH) Stock Price
Media stories about Zimmer Biomet Holdings (NYSE:ZBH) have trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Zimmer Biomet Holdings earned a daily sentiment score of 0.15 on Accern’s scale. Accern also assigned press coverage about the medical equipment provider an impact score of 46.4054218640873 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news stories that may have impacted Accern Sentiment’s scoring:
- Reviewing Zimmer Biomet Holdings (NYSE:ZBH) and CryoLife (CRY) (americanbankingnews.com)
- New Strong Sell Stocks for August 14th (finance.yahoo.com)
- Zimmer Biomet Holdings, Inc. – Value Analysis (NYSE:ZBH) : August 12, 2017 (finance.yahoo.com)
- Zimmer Biomet Holdings, Inc. (ZBH) Stake Boosted by Heritage Investors Management Corp (campdesrecrues.com)
- Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Stake Decreased by Arrow Financial Corp (overnewsmagazine.com)
Several brokerages have recently issued reports on ZBH. Oppenheimer Holdings, Inc. set a $137.00 price target on shares of Zimmer Biomet Holdings and gave the stock a “buy” rating in a report on Monday. Zacks Investment Research downgraded shares of Zimmer Biomet Holdings from a “hold” rating to a “strong sell” rating in a report on Tuesday, August 8th. BidaskClub downgraded shares of Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. BMO Capital Markets upped their price target on shares of Zimmer Biomet Holdings from $136.00 to $140.00 and gave the stock an “outperform” rating in a report on Friday, July 28th. Finally, Leerink Swann upped their price target on shares of Zimmer Biomet Holdings from $141.00 to $146.00 and gave the stock an “outperform” rating in a report on Friday, July 28th. Four analysts have rated the stock with a sell rating, seven have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $136.90.
Shares of Zimmer Biomet Holdings (ZBH) traded up 0.41% during mid-day trading on Tuesday, reaching $112.97. 1,355,997 shares of the company’s stock were exchanged. The company has a 50 day moving average price of $124.00 and a 200-day moving average price of $121.30. Zimmer Biomet Holdings has a one year low of $95.63 and a one year high of $133.49. The stock has a market cap of $22.84 billion, a PE ratio of 32.18 and a beta of 1.20.
Zimmer Biomet Holdings (NYSE:ZBH) last announced its earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share for the quarter, missing analysts’ consensus estimates of $2.10 by $0.02. The company had revenue of $1.95 billion for the quarter, compared to the consensus estimate of $1.95 billion. Zimmer Biomet Holdings had a net margin of 9.12% and a return on equity of 16.70%. The company’s revenue for the quarter was up 1.1% on a year-over-year basis. During the same period in the previous year, the firm posted $2.02 EPS. On average, analysts predict that Zimmer Biomet Holdings will post $8.24 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Friday, September 22nd will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.85%. The ex-dividend date is Thursday, September 21st. Zimmer Biomet Holdings’s payout ratio is 27.59%.
In other news, insider Sang Yi sold 17,731 shares of Zimmer Biomet Holdings stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $124.56, for a total transaction of $2,208,573.36. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Tony W. Collins sold 16,986 shares of Zimmer Biomet Holdings stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $121.74, for a total transaction of $2,067,875.64. The disclosure for this sale can be found here. Insiders own 1.07% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Zimmer Biomet Holdings (ZBH) Stock Price” was first reported by Watch List News and is owned by of Watch List News. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://www.watchlistnews.com/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-zimmer-biomet-holdings-zbh-stock-price/1492500.html.
About Zimmer Biomet Holdings
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.